NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india) arrow 10459.70 -125.05 -1.18%
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Arvind Remedies Limited (NSE: ARVINDREM)

 

ARVINDREM Share Price

Open N/A Change Price %
High N/A 1 Day N/A N/A
Low N/A 1 Week N/A N/A
Close N/A 1 Month N/A N/A
Volume N/A 1 Year N/A N/A
52 Week High N/A
52 Week Low N/A
 
ARVINDREM Technical Analysis
1
As on N/A ARVINDREM Share Price closed @ N/A and we RECOMMEND N/A for LONG-TERM with Stoploss of N/A & N/A for SHORT-TERM with Stoploss of N/A we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 
NSE INDIA Most Active Stocks
JPASSOCIAT 6.80 -7.48%
SOUTHBANK 14.85 1.71%
ADANIPOWER 34.45 -3.77%
RCOM 11.35 -3.81%
DHFL 235.90 -12.24%
SUZLON 6.05 -6.20%
YESBANK 231.90 -6.83%
GMRINFRA 15.70 -4.85%
PNB 66.50 -4.93%
ASHOKLEY 114.30 -5.18%
 
NSE INDIA Top Gainers Stocks
BLUECHIP 0.20 33.33%
MVL 0.25 25.00%
MVL 0.25 25.00%
SPYL 0.30 20.00%
MINDTECK 50.70 13.42%
ENERGYDEV 11.05 13.33%
CINELINE 51.90 13.07%
RAMANEWS 27.80 12.10%
SMPL 0.50 11.11%
ANKITMETAL 0.50 11.11%
 
NSE INDIA Top Losers Stocks
VISESHINFO 0.05 -50.00%
ATNINTER 0.10 -33.33%
FCSSOFT 0.20 -20.00%
IBULHSGFIN 788.65 -13.08%
DBL 468.75 -12.72%
DBL 468.75 -12.72%
DBL 468.75 -12.72%
DHFL 235.90 -12.24%
MANAKALUCO 6.80 -11.69%
DCMSHRIRAM 383.55 -10.79%
 
 
ARVINDREM
Daily Charts
ARVINDREM
Intraday Charts
ARVINDREM
Free Analysis
Premium
Service
 
ARVINDREM Important Levels Intraday
RESISTANCE
RESISTANCE
RESISTANCE
RESISTANCE
RESISTANCE
RESISTANCE
RESISTANCE
RESISTANCE
 
ARVINDREM Target for Month October
4th UP TARGET
3rd UP TARGET
2nd UP TARGET
1st UP TARGET
1st DOWN TARGET
2nd DOWN TARGET
3rd DOWN TARGET
4th DOWN TARGET
 
ARVINDREM Weekly Target
4th UP TARGET
3rd UP TARGET
2nd UP TARGET
1st UP TARGET
1st DOWN TARGET
2nd DOWN TARGET
3rd DOWN TARGET
4th DOWN TARGET
 
ARVINDREM Target for Year 2018
4th UP TARGET
3rd UP TARGET
2nd UP TARGET
1st UP TARGET
1st DOWN TARGET
2nd DOWN TARGET
3rd DOWN TARGET
4th DOWN TARGET
 
 
ARVINDREM Synopsis Technicals View
50 Day EMA N/A (Short Term)
N/A
100 Day EMA N/A (Mid Term) N/A
200 Day EMA N/A (Long Term) N/A
MACD (12 26 9) N/A N/A
RSI (14) N/A N/A
MFI (14) N/A N/A
CCI (20) N/A N/A
WILLIAM %R (14) N/A N/A
ADX (14) N/A N/A
PSAR N/A N/A
10 Day Avg Volume N/A
 
ARVINDREM Other Details
Segment EQ
Market Capital 0.00
Sector Pharmaceuticals
Industry
Offical website
 
ARVINDREM Address
ARVINDREM
N/A
 
ARVINDREM Latest News
We will reassess the NPA situation in 4-6 months: Arvind Panagariya   Economic Times   - 05th May 17
Arvind Remedies Ltd Fixes Book Closure for 27th AGM   Equity Bulls   - 28th Mar 16
Arvind Remedies - Extension to hold Annual General Meeting   Moneycontrol.com   - 31st Dec 15
Arvind Remedies Ltd to go SDR route for restructuring   Equity Bulls   - 29th Nov 15
Arvind Remedies Limited   Moneycontrol.com   - 27th Nov 15
Arvind Remedies Limited   Moneycontrol.com   - 27th Nov 15
BSE to suspend trading in 24 companies from November 27   Moneycontrol.com   - 06th Nov 15
Hold Arvind Remedies, says Meghana Malkan   Moneycontrol.com   - 13th Jul 15
Arvind Remedies - Outcome of Board Meeting   Moneycontrol.com   - 11th Jul 15
Arvind Remedies hits 20% upper circuit   Indiainfoline   - 07th Jul 15
 
Your Comments and Response on Arvind Remedies Limited
 
ARVINDREM Business Profile
Arvind Remedies is in the Pharmaceuticals sector. Arvind Remedies Ltd forayed into the world of quality healthcare in 1988 under the dynamic and ambitious stewardship of Dr.Arvind Shah, Managing Director and CEO. Having established our credibility as a company committed to providing world-class healthcare products, we went Public in April 1996 getting listed in Bombay Stock Exchange & National Stock Exchange in Mumbai, Ahmedabad and Chennai Stock Exchanges. The Public Issue comprised of 30 Lakhs Equity Shares priced at Rs.10/- each at a premium of Rs.20/- per share. In the year 1995 the company was converted to limited company. In January 2001, the Company followed this up with a Rights Issue of 14.86 Lakhs Equity Shares of Rs.10/- each for cash at a premium of Rs.90/- per share. During the year 2010-11 the company has increased its authorized share capital to Rs.66 Crores and paid up capital for Rs.48.23 crores with the addition of preferential issue of 22.50 crores equity shares of Rs.1 each at premium of Rs.1.25 per share. During the year 2012-13 company has started commercial operation of its new facility at irungatukottai,Kancheepuram Dt,Tamil nadu , which is plan for registration under USFDA Arvind Remedies' Indian client portfolio includes prestigious Defence Establishments, ESI, CGHS, Central and State Government Institutions, Public Sector Companies, P&T, Railways and World Bank Projects. We have also won international acceptance and recognition with our exports to Africa, Commonwealth of Independent States and Asian countries The current market capitalisation stands at Rs 307.14 crore.The company has reported a standalone sales of Rs 219.65 crore and a Net Profit of Rs 13.13 crore for the quarter ended Sep 2013. The company management includes B Arvind Shah - Managing Director & CEO, Chandra Ravindran - Whole Time Director, C M K Reddy - Director, R Raja Mohan - Director, V R Mehta - Director, Ankur Agarwal - Executive Director, Sudhir Chandra - Additional Director. It is listed on the BSE with a BSE Code of 531823 and the NSE with an NSE Code of ARVINDREM. Its Registered office is at 190, Poonamallee High Road , Chennai (Madras),Tamil Nadu - 600084.
 
2005-2018 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service